[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337544-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-337544-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","mortality-reduction-and-cumulative-excess-incidence-cei-in-the-prostate-specific-antigen-psa-screening-era","Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era","","Prostate-specific antigen (PSA) screening’s relationship to prostate cancer mortality reduction remains controversial. Using US SEER data from 1980 to 2016, researchers examined the association between cumulative excess incidence (CEI) and prostate cancer mortality in a PSA screening era and evaluated how race modifies this relationship. CEI was treated as a surrogate for screening intensity. Analysis of 163,982,733 person-years and 544,058 prostate cancers showed strong inverse linear links between CEI and mortality and estimated 317,356 deaths avoided. Eight regions reported 46.0–63.7% reductions, with greater lives saved among black men in several registries. A main CEI effect was significant, while factors independent of CEI explained 14.6% of benefit. Minority populations experienced substantial mortality reductions alongside PSA mass utilization.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mortality-reduction-and-cumulative-excess-incidence-cei-in-the-prostate-specific-antigen-psa-screening-era/337544/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mortality-reduction-and-cumulative-excess-incidence-cei-in-the-prostate-specific-antigen-psa-screening-era/337544.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What does CEI represent in this study of PSA screening?","Question",{"text":63,"@type":64},"CEI is used as a surrogate measure for the intensity of prostate cancer screening with PSA testing and subsequent biopsy when appropriate.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data and period were analyzed?",{"text":68,"@type":64},"The study analyzed US Surveillance, Epidemiology, and End Results (SEER) data from 1980 to 2016 for men aged 40–84, including all prostate cancer cases regardless of stage at diagnosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationship did the study find between CEI and prostate cancer mortality?",{"text":72,"@type":64},"Strong inverse linear relationships were observed between CEI and prostate cancer mortality, indicating mortality reduction associated with higher CEI.",{"name":74,"@type":61,"acceptedAnswer":75},"Did the study attribute the mortality benefit only to screening intensity?",{"text":76,"@type":64},"The main effect of CEI was significant, while factors independent of CEI (potentially including treatment advances) explained 14.6% of the mortality benefit.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},337544,1790916680,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":121,"preview_page_count":33,"preview_urls":148},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMortality reduction and cumulative excess incidence (CEI)  \nin the prostate‑specific antigen (PSA) screening era  \nPatrick W. McLaughlin1,2,7, Matthew M. Cousins1,3,7*, Alex Tsodikov4, Payal D. Soni 5 & Juanita M. Crook6  \nThe extent to which PSA screening is related to prostate cancer mortality reduction in the United States (US) is controversial. US Surveillance, Epidemiology, and End Results Program (SEER) data from 1980 to 2016 were examined to assess the relationship between prostate cancer mortality and cumulative excess incidence (CEI) in the PSA screening era and to clarify the impact of race on this relationship. CEI was considered as a surrogate for the intensity of prostate cancer screening with PSA testing and subsequent biopsy as appropriate. Data from 163,982,733 person‑years diagnosed with 544,058 prostate cancers (9 registries, 9% of US population) were examined. Strong inverse linear relationships were noted between CEI and prostate cancer mortality, and 317,356 prostate cancer deaths were avoided. Eight regions of the US demonstrated prostate cancer mortality reduction of  \n46.0–63.7%. On a per population basis, the lives of more black men than white men were saved in three of four registries with sufficient black populations for comparison. Factor(s) independent ofCEI (potential effects of treatment advances) explained 14.6% of the mortality benefit (p‑value = 0.3357) while there was a significant main effect ofCEI (effect = −0.0064; CI: [−0.0088, −0.0040];  \np‑value \u003C 0.0001). Therefore, there is a strong relationship between CEI and prostate cancer mortality reduction that was not related to factors independent of screening utilization. Minority populations have experienced large mortality reductions in the context of PSA mass utilization.  \nWith mass utilization of prostate-specific antigen (PSA) screening for prostate cancer beginning in the late 1980s, prostate cancer mortality and disease characteristics at presentation changed profoundly. Before the introduction of PSA testing, 20% of Caucasians and 40% of African Americans (AA) had metastatic disease at diagnosis1,2. After PSA screening was introduced, metastases at diagnosis declined, and within 10 years, annual mortality began to fall2. Randomized controlled trials sought to clarify the relationship between PSA screening and prostate cancer mortality in predominantly Caucasian populations3.  \nTwo large randomized controlled trials had major impacts on policy and patient management4,5. The Prostate Lung Colorectal Ovarian (PLCO) study randomized 76,693 men to PSA screening or no screening and concluded that screening did not reduce mortality6. The European Randomized study of Screening for Prostate Cancer (ERSPC) randomized 162,387 men to PSA screening or no screening and found a 20% reduction in prostate cancer mortality in the screening arm5. Alternative explanations for mortality reduction seen with mass utilization of PSA screening, such as improved treatment, gained prominence7–9. Considering these trials, the U.S. Preventative Services Task Force (USPSTF) recommended against PSA screening in 2012.  \nThe conclusion that PSA screening does not reduce prostate cancer mortality is under scrutiny. A follow-up analysis of the PLCO and ERSPC that addressed contamination and compliance suggested that mortality was indeed reduced by PSA screening10, 11. USPSTF guidance was later modified in favor of selected screening in  \n1Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. 2Department of Radiation Oncology, Assarian Cancer Center, Ascension Providence Hospital, Novi, MI, USA. 3Department of Advanced Radiation Oncology, Self Regional Healthcare, Greenwood, SC, USA. 4Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. 5Department of Radiation Oncology, Dignity Health Cancer Institute, Phoenix, AZ, USA. 6","cbCaioVFT39zjjUs","https://ap.wps.com/l/cbCaioVFT39zjjUs","pdf",1337242,"English","# Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era\n## Background and controversy\n## Study hypothesis and objectives\n## Methods\n## Data sources\n## Mortality, incidence, and screening utilization","[{\"question\":\"What does CEI represent in this study of PSA screening?\",\"answer\":\"CEI is used as a surrogate measure for the intensity of prostate cancer screening with PSA testing and subsequent biopsy when appropriate.\"},{\"question\":\"What data and period were analyzed?\",\"answer\":\"The study analyzed US Surveillance, Epidemiology, and End Results (SEER) data from 1980 to 2016 for men aged 40–84, including all prostate cancer cases regardless of stage at diagnosis.\"},{\"question\":\"What relationship did the study find between CEI and prostate cancer mortality?\",\"answer\":\"Strong inverse linear relationships were observed between CEI and prostate cancer mortality, indicating mortality reduction associated with higher CEI.\"},{\"question\":\"Did the study attribute the mortality benefit only to screening intensity?\",\"answer\":\"The main effect of CEI was significant, while factors independent of CEI (potentially including treatment advances) explained 14.6% of the mortality benefit.\"}]","Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era | PDF",1790019575,[149,153,157,161],{"page_no":22,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1107a7f51ec8bf582994b0db8751fd2d.webp",983,1291,{"page_no":26,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5849c55098176410d24af4fd58dbf2f.webp",982,1290,{"page_no":30,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0446e58b0cb9f2306f7d746436aea9d.webp",981,1289,{"page_no":33,"url":162,"width":163,"height":164},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc24333dc165dfaf78a4a640d282e1bb.webp",980,1287]